Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Ch...

The Role of Biomarkers in HR-Positive/HER2-Negative Early Breast Cancer: From Clinical Analysis t...Подробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее

New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identificationПодробнее

Dr. Denduluri on the Use of the Oncotype DX Assay in Early-Stage HR+/HER2- Breast CancerПодробнее

Adjuvant therapy for early stage ER-positive, HER2-negative invasive breast cancerПодробнее

Hormonal Positive Breast Cancer: Detection, Treatment & Risk AssessmentПодробнее

How to use endocrine therapy in premenopausal women with ER+ early breast cancerПодробнее

Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...Подробнее

Important considerations in the management of HR+, HER2-negative early breast cancerПодробнее

Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: The Adjuvant Clinical Trial Populat...Подробнее

Hormone Receptor-Positive (HR+) Breast Cancer: Treatment Options ExplainedПодробнее

Update from KAITLIN for high-risk HER2-positive early breast cancerПодробнее

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast CancerПодробнее

Reducing the Risk of Recurrence In HR+/HER2- Early Breast Cancer Requires Action: MDT Clinical Ca...Подробнее

Ask the expert: Early-stage HER2-positive breast cancer with Adrienne Waks, MDПодробнее

Updates in Extended Endocrine Therapy for HR+ Breast Cancer | ASCO21 & National Practice GuidelinesПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

Prognostic score in early HR+/HER2- breast cancer: RS, factors, mutations, histologyПодробнее

Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast CancerПодробнее